AAPL356.27+1.39 (+0.39%) ▲|ABBV295.03+0.58 (+0.20%) ▲|ABT108.52+1.27 (+1.18%) ▲|ACN250.49+0.54 (+0.22%) ▲|ADBE243.08+4.54 (+1.90%) ▲|AMAT370.50-10.45 (-2.74%) ▼|AMD534.06-51.24 (-8.75%) ▼|AMGN465.67-1.39 (-0.30%) ▼|AMT191.64+1.85 (+0.97%) ▲|AMZN266.66-0.78 (-0.29%) ▼|AVGO347.01-17.35 (-4.76%) ▼|AXP320.60+2.54 (+0.80%) ▲|BA171.50-0.05 (-0.03%) ▼|BAC51.02+0.51 (+1.01%) ▲|BKNG159.58-1.62 (-1.01%) ▼|BLK1,222.91+6.30 (+0.52%) ▲|BMY63.43+1.11 (+1.78%) ▲|BNY153.41+0.62 (+0.41%) ▲|BRK-B592.94+3.11 (+0.53%) ▲|C124.01-0.05 (-0.04%) ▼|CAT600.20-5.08 (-0.84%) ▼|CL99.67+1.77 (+1.81%) ▲|CMCSA25.16+0.36 (+1.45%) ▲|COF195.08+1.48 (+0.76%) ▲|COP142.28+2.22 (+1.59%) ▲|COST1,106.21+14.00 (+1.28%) ▲|CRM217.84+0.27 (+0.12%) ▲|CSCO95.64-6.37 (-6.24%) ▼|CVS89.35-0.44 (-0.49%) ▼|CVX219.89+3.54 (+1.64%) ▲|DE673.54-5.25 (-0.77%) ▼|DHR233.02+0.86 (+0.37%) ▲|DIS118.97+0.74 (+0.63%) ▲|DUK129.16+1.66 (+1.30%) ▲|EMR166.38+0.06 (+0.03%) ▲|FDX324.14+4.84 (+1.52%) ▲|GD363.46+0.39 (+0.11%) ▲|GE331.81+0.95 (+0.29%) ▲|GEV803.13-15.36 (-1.88%) ▼|GILD168.08+0.13 (+0.08%) ▲|GM86.00-0.25 (-0.29%) ▼|GOOG292.52-2.83 (-0.96%) ▼|GOOGL295.77-2.93 (-0.98%) ▼|GS916.56+2.96 (+0.32%) ▲|HD348.69+0.43 (+0.12%) ▲|HON222.46-0.29 (-0.13%) ▼|IBM247.13+2.46 (+1.01%) ▲|INTC59.66-1.54 (-2.52%) ▼|INTU341.70+1.53 (+0.45%) ▲|ISRG443.59+3.70 (+0.84%) ▲|JNJ285.75+2.23 (+0.79%) ▲|JPM346.19+3.37 (+0.98%) ▲|KO99.25+1.81 (+1.86%) ▲|LIN526.06+3.57 (+0.68%) ▲|LLY1,443.50+17.95 (+1.26%) ▲|LMT596.04-8.05 (-1.33%) ▼|LOW227.73+0.27 (+0.12%) ▲|LRCX225.92-7.86 (-3.36%) ▼|MA661.19+8.59 (+1.32%) ▲|MCD271.97-1.66 (-0.61%) ▼|MDLZ67.54+0.98 (+1.47%) ▲|MDT102.86+1.87 (+1.85%) ▲|META641.69+18.08 (+2.90%) ▲|MMM183.66-1.80 (-0.97%) ▼|MO78.64+0.72 (+0.92%) ▲|MRK147.76+0.81 (+0.55%) ▲|MS190.65+1.48 (+0.78%) ▲|MSFT523.88+0.88 (+0.17%) ▲|MU778.31-20.13 (-2.52%) ▼|NEE85.12-0.17 (-0.20%) ▼|NFLX62.15-0.54 (-0.86%) ▼|NKE37.99+0.23 (+0.61%) ▲|NOW102.25+1.59 (+1.58%) ▲|NVDA162.85-3.34 (-2.01%) ▼|ORCL125.35-1.76 (-1.38%) ▼|PEP145.44+3.18 (+2.24%) ▲|PFE28.89+0.06 (+0.21%) ▲|PG169.80+1.77 (+1.05%) ▲|PLTR167.99-3.59 (-2.09%) ▼|PM198.96+2.30 (+1.17%) ▲|QCOM172.47-4.67 (-2.64%) ▼|RTX198.58+0.22 (+0.11%) ▲|SBUX106.44-0.19 (-0.18%) ▼|SCHW92.98+1.58 (+1.73%) ▲|SO93.59+1.12 (+1.21%) ▲|SPG232.97-0.64 (-0.27%) ▼|T22.18+0.00 (+0.00%) ▲|TMO700.22+0.78 (+0.11%) ▲|TMUS169.95-1.08 (-0.63%) ▼|TSLA390.22-7.23 (-1.82%) ▼|TXN303.60-8.88 (-2.84%) ▼|UBER69.69+0.57 (+0.82%) ▲|UNH407.46+2.33 (+0.58%) ▲|UNP302.44-1.76 (-0.58%) ▼|UPS112.40+2.02 (+1.83%) ▲|USB60.99+0.52 (+0.86%) ▲|V425.76+5.45 (+1.30%) ▲|VZ46.36-0.19 (-0.41%) ▼|WFC86.05+0.29 (+0.34%) ▲|WMT128.09+1.90 (+1.51%) ▲|XOM170.59+0.81 (+0.48%) ▲|AAPL356.27+1.39 (+0.39%) ▲|ABBV295.03+0.58 (+0.20%) ▲|ABT108.52+1.27 (+1.18%) ▲|ACN250.49+0.54 (+0.22%) ▲|ADBE243.08+4.54 (+1.90%) ▲|AMAT370.50-10.45 (-2.74%) ▼|AMD534.06-51.24 (-8.75%) ▼|AMGN465.67-1.39 (-0.30%) ▼|AMT191.64+1.85 (+0.97%) ▲|AMZN266.66-0.78 (-0.29%) ▼|AVGO347.01-17.35 (-4.76%) ▼|AXP320.60+2.54 (+0.80%) ▲|BA171.50-0.05 (-0.03%) ▼|BAC51.02+0.51 (+1.01%) ▲|BKNG159.58-1.62 (-1.01%) ▼|BLK1,222.91+6.30 (+0.52%) ▲|BMY63.43+1.11 (+1.78%) ▲|BNY153.41+0.62 (+0.41%) ▲|BRK-B592.94+3.11 (+0.53%) ▲|C124.01-0.05 (-0.04%) ▼|CAT600.20-5.08 (-0.84%) ▼|CL99.67+1.77 (+1.81%) ▲|CMCSA25.16+0.36 (+1.45%) ▲|COF195.08+1.48 (+0.76%) ▲|COP142.28+2.22 (+1.59%) ▲|COST1,106.21+14.00 (+1.28%) ▲|CRM217.84+0.27 (+0.12%) ▲|CSCO95.64-6.37 (-6.24%) ▼|CVS89.35-0.44 (-0.49%) ▼|CVX219.89+3.54 (+1.64%) ▲|DE673.54-5.25 (-0.77%) ▼|DHR233.02+0.86 (+0.37%) ▲|DIS118.97+0.74 (+0.63%) ▲|DUK129.16+1.66 (+1.30%) ▲|EMR166.38+0.06 (+0.03%) ▲|FDX324.14+4.84 (+1.52%) ▲|GD363.46+0.39 (+0.11%) ▲|GE331.81+0.95 (+0.29%) ▲|GEV803.13-15.36 (-1.88%) ▼|GILD168.08+0.13 (+0.08%) ▲|GM86.00-0.25 (-0.29%) ▼|GOOG292.52-2.83 (-0.96%) ▼|GOOGL295.77-2.93 (-0.98%) ▼|GS916.56+2.96 (+0.32%) ▲|HD348.69+0.43 (+0.12%) ▲|HON222.46-0.29 (-0.13%) ▼|IBM247.13+2.46 (+1.01%) ▲|INTC59.66-1.54 (-2.52%) ▼|INTU341.70+1.53 (+0.45%) ▲|ISRG443.59+3.70 (+0.84%) ▲|JNJ285.75+2.23 (+0.79%) ▲|JPM346.19+3.37 (+0.98%) ▲|KO99.25+1.81 (+1.86%) ▲|LIN526.06+3.57 (+0.68%) ▲|LLY1,443.50+17.95 (+1.26%) ▲|LMT596.04-8.05 (-1.33%) ▼|LOW227.73+0.27 (+0.12%) ▲|LRCX225.92-7.86 (-3.36%) ▼|MA661.19+8.59 (+1.32%) ▲|MCD271.97-1.66 (-0.61%) ▼|MDLZ67.54+0.98 (+1.47%) ▲|MDT102.86+1.87 (+1.85%) ▲|META641.69+18.08 (+2.90%) ▲|MMM183.66-1.80 (-0.97%) ▼|MO78.64+0.72 (+0.92%) ▲|MRK147.76+0.81 (+0.55%) ▲|MS190.65+1.48 (+0.78%) ▲|MSFT523.88+0.88 (+0.17%) ▲|MU778.31-20.13 (-2.52%) ▼|NEE85.12-0.17 (-0.20%) ▼|NFLX62.15-0.54 (-0.86%) ▼|NKE37.99+0.23 (+0.61%) ▲|NOW102.25+1.59 (+1.58%) ▲|NVDA162.85-3.34 (-2.01%) ▼|ORCL125.35-1.76 (-1.38%) ▼|PEP145.44+3.18 (+2.24%) ▲|PFE28.89+0.06 (+0.21%) ▲|PG169.80+1.77 (+1.05%) ▲|PLTR167.99-3.59 (-2.09%) ▼|PM198.96+2.30 (+1.17%) ▲|QCOM172.47-4.67 (-2.64%) ▼|RTX198.58+0.22 (+0.11%) ▲|SBUX106.44-0.19 (-0.18%) ▼|SCHW92.98+1.58 (+1.73%) ▲|SO93.59+1.12 (+1.21%) ▲|SPG232.97-0.64 (-0.27%) ▼|T22.18+0.00 (+0.00%) ▲|TMO700.22+0.78 (+0.11%) ▲|TMUS169.95-1.08 (-0.63%) ▼|TSLA390.22-7.23 (-1.82%) ▼|TXN303.60-8.88 (-2.84%) ▼|UBER69.69+0.57 (+0.82%) ▲|UNH407.46+2.33 (+0.58%) ▲|UNP302.44-1.76 (-0.58%) ▼|UPS112.40+2.02 (+1.83%) ▲|USB60.99+0.52 (+0.86%) ▲|V425.76+5.45 (+1.30%) ▲|VZ46.36-0.19 (-0.41%) ▼|WFC86.05+0.29 (+0.34%) ▲|WMT128.09+1.90 (+1.51%) ▲|XOM170.59+0.81 (+0.48%) ▲|

4.8 C

New York

Saturday, November 14, 2026

Systemair secures first order for air handling units with integrated heat pump and natural refrigerant

Pentixapharm Announces Progress of Pivotal Phase 3 PANDA Study; Will Host Third Quarter Webcast on November 12, 2026

Sinch Announces Joining the Inaugural SpaceX Super Intelligence Network as Marketplace Partner

Tag: year

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub (“HTH”) Accelerator Program. Based in Boston, Massachusetts, home to more than 1,000 biotech companies¹, HTH is operated by the Advanced Regenerative Manufacturing Institute (“ARMI”) and its BioFabUSA initiative.

ENGWE Will Present Its New Product Line MapFour at Eurobike with Upgraded Models

FRANKFURT, Germany, June 20, 2025 /PRNewswire/ -- ENGWE, a global leader in electric mobility, will showcase its latest innovations at Eurobike 2025, held in Frankfurt...

Prosafe SE: Operational update – May 2025

20 June 2025 - Fleet utilisation for May 2025 was 60 per cent.

LPS and QAX Announce Strategic Partnership for Cybersecurity, Unveiling Security Operation Centre and End-to-End Security Services

The duo's first joint Security Operation Centre (SOC) in Hong Kong addresses the urgent need for advanced cybersecurity defenses amidst surging cyber threats.The new SOC...

New Global Aesthetics Report: A Shift Towards Facial Surgery Globally as Eyelid Ranks Top Procedure

Aesthetic Procedures Close to 38 Million in 2024. MOUNT ROYAL, N.J., June 20, 2025 /CNW/ -- The International Society of Aesthetic Plastic Surgery (ISAPS) released the...

Tariff Dodging Complaints Soar—Surprised?

US Customs and Border Protection (CBP) has seen a spike in reports of tariff dodging since Trump slapped new duties on over 100 countries....

eBay and Vestiaire Beg for Tariff Mercy

Last month, Suzanne Smith-Darley thought she snagged a deal on a used Chanel bag from Japan for $800 on eBay. Then, DHL slapped her...

BC Tech Pioneers Quality Upgrade in PV Industry

SHANGHAI, June 20, 2025 /PRNewswire/ -- During the recent 2025 SNEC exhibition in Shanghai, LONGi, a global leader in PV technology innovation, signed a strategic...

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

Analyzing Annuity Costs: A Detailed Breakdown for Strategic Financial Planning

Annuities, while potentially beneficial under certain circumstances, require careful scrutiny due to their associated costs. The primary concern is the substantial fees that can...

Avoid These Costly Social Security Mistakes: A Strategic Guide for Investors

Navigating Social Security requires precision, particularly when considering the impact on long-term financial planning. While the process appears straightforward—apply, update your information, and wait—strategic...

Fed Maintains Interest Rates—Evaluate Implications for Credit Cards, Auto Loans, Mortgages

The Federal Reserve's decision to maintain the current interest rate reflects a strategic pause amid an evolving economic landscape. Given President Trump's calls for...

SBI Life crowdsources future-facing AI solutions from India’s Next-Gen Talent pool at the 2025 Hack-AI-Thon finale

The initiative underscored SBI Life's focus on innovation, young talent, and building future-ready insurance solutions MUMBAI, India, June 20, 2025 /PRNewswire/ -- SBI Life Insurance,...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsYear